AUTHORS
Zefeng Xu, Ling Pan2, Zhenya Hong3, Qingsong Yin, PhD4, Xue Lan Zuo5, Wen Qin, MD6, Lihong Li7, Xin Du, MD, PhD8, Chunkang Chang9, Zhijian Xiao10
AFFILIATIONS
1 Blood Disease Hospital and Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin, China
2 West China Hospital, Sichuan University, Sichuan, China
3 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
4 Henan Cancer Hospital, Henan, China
5 Zhongnan Hospital of Wuhan University, Wuhan, China
6 The Second Affiliated Hospital of Army Medical University, PLA, Chongqing, China
7 Beijing Tsinghua Changgung Hospital, Beijing, China
8 Guangdong Provincial People's Hospital, Guangzhou, China
9 Shanghai Sixth People's Hospital, Shanghai, China
10 MDS and MPN Center, Blood Disease Hospital and Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin, China
ABSTRACT
Background: TQ05105(rovadicitinib) is a first-in-class, dual JAK/ROCK inhibitor, which has been approved in China for treatment of myelofibrosis (MF). TQ05105-I-01 is a single-arm, open-label, multicenter phase I study of rovadicitinib in myeloproliferative neoplasms (MPN) patients comprising a dose-escalation phase (N=15) and an expansion phase(N=49) (NCT04339400). Among MF patients at the TQ05105-I-01 study (N=45), the primary efficacy analysis reported a spleen volume reduction ≥35% (SVR35) rate of 28.9% at week 24, and a best SVR35 rate of 57.8%; the total symptom score reduction ≥50% (TSS50) rate was 71.1% at week 24, and a best TSS50 rate was 88.9%. Here we further report the detailed analysis of MF grade improvement from this study.
Methods: During the TQ05105-I-01 study, bone marrow biopsies were performed at screening, week 24, week 48, week 96, and end of follow-up in MF patients. Reticulin silver staining was used, and MF grade was assessed according to the 2016 WHO criteria. Kaplan-Meier analysis was applied to describe time to first MF grade improvement events, and 1-year improvement rate was estimated.
Results: Median follow-up time was 11.5months. Median age was 59.0, and percentage of male and female patients were 67.4% and 32.6%. A total of 43 patients received the target dose of 15 mg BID and had evaluable baseline and on-treatment biopsies. Baseline MF grade distribution was: MF-1, 9.3% (4/43); MF-2, 37.2% (16/43); MF-3, 53.5% (23/43). By week 24 assessment, 12 patients (27.9%) showed an improvement of ≥1 grade, and 26 patients (60.5%) showed stable MF grade compared to baseline. The best observed improvement rate during follow-up was 34.9% (15/43). Among the patients who experienced improvement, the improved state was sustained, including 3 patients (1 MF-3 and 2 MF-1 patients at baseline) who progressively improved to MF-0 grade during follow up. Estimated 1-year MF grade improvement rate was 39.5% (95% CI: 20.0%-54.2%).
Conclusions: In the TQ05105-I-01 study, rovadicitinib monotherapy at 15 mg BID demonstrated MF grade improvement. The improvement was sustained in patients during whole follow-up period. These data suggest that TQ05105 may have a potential advantage in delaying or reversing myelofibrosis progression.
DISCLOSURES
Zefeng Xu: No relevant conflicts of interest to declare.